General Information of Drug (ID: DMJ1YQ2)

Drug Name
Epeleuton
Synonyms
Epeleuton; Epeleuton [INN]; 1667760-39-5; FA9BPX1T6V; (S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; UNII-FA9BPX1T6V; 15(S)-HEPE-EE; CHEMBL5095178; AKOS040748327; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER
Indication
Disease Entry ICD 11 Status REF
Hypertriglyceridemia 5C80.1 Phase 2 [1]
Non-alcoholic fatty liver disease DB92 Phase 2 [2]
Sickle-cell disorder 3A51 Phase 2 [3]
Type 2 diabetes 5A11 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C22H34O3
Canonical SMILES
CCC=CCC(C=CC=CCC=CCC=CCCCC(=O)OCC)O
InChI
InChI=1S/C22H34O3/c1-3-5-15-18-21(23)19-16-13-11-9-7-6-8-10-12-14-17-20-22(24)25-4-2/h5-7,10-13,15-16,19,21,23H,3-4,8-9,14,17-18,20H2,1-2H3/b7-6-,12-10-,13-11-,15-5-,19-16+/t21-/m0/s1
InChIKey
DJYKWMOPVZGTRJ-PILRRHKESA-N
Cross-matching ID
PubChem CID
133082733
TTD ID
DV8F9L
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT02941549) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05861453) An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease. U.S.National Institutes of Health.